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Abstract
Background: The induction of tumor cell invasion is an important step in tumor progression. Due
to the cost and slowness of in-vivo invasion assays, there is need for quantitative in-vitro invasion
assays that mimic as closely as possible the tumor environment and in which conditions can be
rigorously controlled.
Methods: We have established a novel asymmetric 3D in-vitro invasion assay by embedding a
monolayer of tumor cells between two layers of collagen. The cells were then allowed to invade
the upper and lower layers of collagen. To visualize invading cells the gels were sectioned
perpendicular to the monolayer so that after seeding the monolayer appears as a thin line precisely
defining the origin of invasion. The number of invading tumor cells, their proliferation rate, the
distance they traverse and the direction of invasion could then be determined quantitatively.
Results: The assay was used to compare the invasive properties of several tumor cell types and
the results compare well with those obtained by previously described assays. Lysyl-oxidase like
protein-2 (Loxl2) is a potent inducer of invasiveness. Using our assay we show for the first time
that inhibition of endogenous Loxl2 expression in several types of tumor cells strongly inhibits their
invasiveness. We also took advantage of the asymmetric nature of the assay in order to show that
fibronectin enhances the invasiveness of breast cancer cells more potently than laminin. The
asymmetric properties of the assay were also used to demonstrate that soluble factors derived
from fibroblasts can preferentially attract invading breast cancer cells.
Conclusion: Our assay displays several advantages over previous invasion assays as it is allows the
quantitative analysis of directional invasive behavior of tumor cells in a 3D environment mimicking
the tumor microenvironment. It should be particularly useful for the study of the effects of
components of the tumor microenvironment on tumor cell invasiveness.
Background
The transition from the non-invasive phenotype to the
invasive phenotype of tumor cells marks the transition
from a relatively benign tumor that can be successfully
treated surgically to a more malignant form of cancer [1].
Despite many in vivo studies of tumor cell invasion, the
amount of information derived from such in vivo studies
is somewhat limited due to the complex microenviron-
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ment of tumors, due to the inherent variability frequently
encountered in in-vivo assays, and due to the cost of in-
vivo assays. This problem can be partially overcome by
studying invasive processes in relatively inexpensive in-
vitro tumor progression assays in which conditions can be
accurately controlled. However, for meaningful results
such in-vitro systems should mimic as closely as possible
in-vivo conditions.
In-vitro 3D invasion assays can be divided into three gen-
eral types. The first is represented by Boyden chamber and
similar filter-based invasion assays in which tumor cells
are seeded on top of a gel composed of extracellular
matrix (ECM)-derived proteins which sits on top of a fil-
ter. The cells are allowed to invade and cells that pass to
the other side of the filter are counted [2,3]. The advantage
of this type of assay is speed and ease of quantitative deter-
mination. However, only the end point is monitored, the
cells that successfully invaded usually represent only a
small fraction of the entire population of tumor cells and
may only represent a subpopulation of the tumor cells.
Thus, results obtained in such assays may be misleading.
In the second type of assay cells are seeded as suspensions
in gels composed of ECM components and their migra-
tion in the gel is monitored [4,5]. Alternatively, the tumor
cells are pre-formed into spheroids which are subse-
quently suspended in the gels or seeded on top of gels.
The migration of the implanted cells out of the spheroids
is then monitored [6-9]. These types of assays are much
slower and are generally difficult to quantify because of
the absence of a sharply defined origin of migration. Thus
quantification relies on the tracking of individual cells
within the population or on semi-quantitative assess-
ments of the expansion of implanted spheroids. In the
third type of assay, cells are seeded on top of a gel com-
posed of ECM components. The cells adhere forming a
monolayer and subsequently invade the gel. This is very
similar to the Boyden chamber based assays except that in
these assays various methods are used to track invading
cells and the assays do not simply rely on the counting of
cells able to traverse a filter [10,11]. In these assays the
start position is clearly defined by the upper surface of the
gel aiding quantification and the whole population of
cells can be observed but the assays take much more time
as compared with Boyden chamber based assays. A major
problem of this type of assay is that at the start position
cells are located at an interface between liquid and gel and
are not embedded completely as they embedded in-vivo.
Furthermore, this assay is unidirectional, and it is there-
fore difficult to compare the effects of different external
factors on the invasive properties of the tumor cells.
We describe a novel 3D invasion assay in which in the ini-
tial "start" position tumor cells are seeded in a monolayer
between two gel layers. In this assay the cells are com-
pletely embedded in the ECM from the start. The effects of
various constituents of the tumor microenvironment on
the invasive behavior of tumor cells can be compared by
differentially varying the composition of the microenvi-
ronment that tumor cells encounter above or below the
tumor cell monolayer. Thus, it is possible, for example, to
embed different types of normal cells in the ECM above or
below the monolayer of tumor cells and directly compare
their effects on tumor cell invasiveness in a single experi-
ment. Furthermore, since at the beginning of the assay the
cells are arranged in a monolayer that defines a sharp ori-
gin of migration, this assay is also easily quantifiable and
provides information on behavior of the entire popula-
tion of the tumor cells.
Methods
Reagents
The  ΔNRF (pCMVdR8.74) and pMD2-VSVG plasmids
were given to us by Dr. Tal Kafri (Department of Microbi-
ology and Immunology, University of North Carolina). A
human Loxl2 specific shRNA lentiviral plasmid set was
purchased from Sigma (MISSION shRNA Bacterial Glyc-
erol Stock NM-002318). Two of the shRNA's
(TRCN46195 and TRCN46197) efficiently inhibited
Loxl2 expression (data not shown). The MISSION Non-
Target shRNA Control Vector was purchased from Sigma
(SHC002). The vital fluorescent dyes DiI and DiAsp were
purchased from Molecular Probes (Eugene, OR). Eosin-Y
was from Pioneer Research Chemicals, UK. Mayer's hema-
toxylin was from Sigma. Laminin-1 derived from Engel-
breth-Holm-Swarm (EHS) tumors was kindly provided by
Dr. Hynda Kleinman (NIH, Bethesda, Maryland, USA).
Rat tail collagen was also purchased from Trevigen (Gaith-
ersburg, USA).
Cells
The MDA-MB-231 cells were kindly provided by Dr.
Michael Klagsbrun (Harvard University, USA). The LM2-4
cells were provided by Dr. Robert Kerbel from Sunny-
brook and Women's College Health Sciences Centre,
Toronto, Canada. HT1080 cells were provided to us by Dr.
Varda Rotter (Weizmann institute, Israel). The MDA-MB-
435 and HEK293-T cells were purchased from the ATCC.
Human foreskin fibroblasts were isolated as described
[12]. The cells were grown in DMEM supplemented with
4.5 g/ml glucose, 10% FCS, 2 mM Glutamine, 50 μg/ml
gentamicin, 2.5 μg/ml fungizone, in a humidified incuba-
tor at 37°C, 5% CO2.
Preparation of rat tail collagen
Tails were removed from freshly killed adult rats and were
cleaned by brief washing in 70% ethanol. The skin was
split at the tail root and peeled away. The distal and prox-
imal quarters of the tail were cut away. Each tendon was
separately dissected using a scalpel and the fibers sepa-BMC Cancer 2009, 9:415 http://www.biomedcentral.com/1471-2407/9/415
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rated. The fibers were rinsed briefly in 70% ethanol,
weighted, and incubated in 0.2% acetic acid (100 ml/gr).
The flask was stirred three to five days at 4°C. Insoluble
debris was separated by centrifugation. The supernatant
was aliquoted and stored at 4°C. Collagen concentration
was determined by weighing following freeze drying of an
aliquot of the supernatant. Similar results were obtained
using a commercial preparation of rat tail collagen.
Invasion assay
Unless otherwise stated, the lower collagen layer was pre-
pared by mixing one volume of tenfold concentrated
M199 growth medium, one volume of 1 mg/ml bovine
fibronectin (final concentration 0.1 mg/ml), 0.1 volume
of 10% FCS (final concentration 1%) and seven volumes
of collagen type I solution (final concentration 1 mg/ml).
2 N NaOH was then added slowly while mixing to bring
the pH to pH-7.3 to obtain a neutralized solution of col-
lagen. All the constituents were kept at 4°C as was the
final solution. Cold collagen solution (0.3 ml) was
poured into 8-wells chamber wells (Nunc) avoiding bub-
ble formation and warmed to 37°C to induce polymeriza-
tion.
Cancer cells were trypsinized and suspended in complete
growth medium. 200 μl containing 5 × 104 cells were
seeded on the top of the lower collagen layer and allowed
to adhere and spread. After two hours, the medium was
aspirated gently and unless otherwise stated, 0.2 ml of the
same cold neutralized collagen solution was added to
cover the cells and to form the upper layer of collagen. The
upper layer was then polymerized at 37°C. For tumor
cells/fibroblasts mixed assays an additional layer of 0.12
ml collagen containing 105 normal human skin fibrob-
lasts (HSF) was formed on top of the upper collagen layer.
Following polymerization, 0.25 ml of growth medium
was added to the wells and the cells were incubated for up
to 9 days in a humidified incubator at 37°C and 5% CO2.
The medium covering the collagen gel was exchanged
every two days.
Preparation of histological sections from gels
The medium was gently aspirated and the gels were fixed
by addition of 0.5 ml of 4% paraformaldehyde in phos-
phate buffered saline (PBS). The 4% paraformaldehyde
solution was exchanged twice at 30 minute intervals. Gels
were then washed with PBS three times at 10 minute inter-
vals. The PBS was then gently aspirated and the gels were
covered with Tissue Embedding Medium (OCT) and incu-
bated overnight at 4°C. The gels were then transferred to
self-prepared aluminum foil molds, embedded with addi-
tional OCT and immediately frozen in isopentane pre-
cooled by liquid nitrogen. Constructs were then flipped
by 90 degrees and cut in a cryostat into 7 μm thick sections
in order to display a perpendicular cross section of the cell
monolayer (Figures 1A and 1B). Sections were air-dried,
rinsed with running water, stained with eosin-Y for 20 sec-
onds, rinsed and counterstained with Mayer's hematoxy-
lin prior to mounting.
Quantification of invasion
Stained sections were viewed at a 10× magnification and
the middle portion of each section was photographed.
The "measure" function of the Image-Pro software was
used to highlight the cells and to count cells in successive
zones 120 μm thick above and below the central line of
cells that did not migrated out of the monolayer (Figure
1A)). The number of stained cells larger than 30 pixels in
each of the 120 μm wide zones was determined. In sym-
metrical experiments in which the upper and lower gels
were similar, the number of the cells that invaded corre-
sponding zones above and below the monolayer was
summed to obtain the number of invading cells in each of
the zones.
Boyden chamber invasion assay
The assay was performed using 24-well Boyden chambers
containing polycarbonate filters with a pore size of 8 μm
essentially as described [3]. The filters were coated with 50
μl of neutralized collagen I solution, and incubated in a
humidified incubator at 37°C to allow polymerization.
The lower compartment was filled with DMEM supple-
mented with 10% fetal calf serum. HT-1080 cells (105
cells/well) expressing Loxl2 targeting or control shRNAs
were suspended in 0.5 ml serum free DMEM and seeded
on top of the collagen in the upper compartment of the
chamber. After incubation at 37°C for 16 h, the cells on
the upper surface of the filter were removed by wiping.
Cells, that transversed the filter were fixed in methanol,
stained with 0.5% crystal violet, and counted.
Inhibition of Loxl2 expression in tumor cells
HEK293-T cells were co-transfected with the lentiviral
plasmid containing the Loxl2 specific shRNA or with a
plasmid containing control unrelated shRNA (8 μg),
along with the packaging vector pCMVdR8.91 (5 μg), and
a plasmid encoding the vesicular stomatitis virus coat
envelope pMD2-VSVG (2 μg) using Fugene-6 according to
the instructions of the vendor and incubated 24 h at
37°C. Conditioned medium containing infective lentivi-
ral particles was collected 48 hours and 72 hours post
transfection, and filtered through 0.45 μ filters and used
for infection of cells. Target cells (105 cells) were incu-
bated with the conditioned medium in the presence of 8
μg/ml polybrene for 8-16 hours. Following infection, cells
were washed twice with PBS, transferred to the regular
growth medium. Stable Loxl2-silenced cells were selected
using 2 μg/ml puromycin. To verify Loxl2 down-regula-
tion, cells were lysed 48-72 hours post infection. Cell
lysates (30 μg) were separated by SDS/PAGE, blotted ontoBMC Cancer 2009, 9:415 http://www.biomedcentral.com/1471-2407/9/415
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nitrocellulose, and probed with antibodies directed
against Loxl2 [13].
Fluorescent labeling of cells
In assays in which both tumor cells and fibroblasts were
used, the tumor cells were labeled with 5 μg/ml DiI (green
fluorescence) by incubation in complete growth medium
for 0.5 h prior to the assay. The human skin derived
fibroblasts (HSF cells) were labeled similarly with 5 μg/ml
DiAsp (red fluorescence).
Statistical analysis
At least three independent experiments were assessed.
Cells in eight to twelve microscopic fields were counted in
each experiment. Error bars represent the standard error of
the mean. The statistical significance of the results was
examined using the unpaired data with unequal variance
student's T-test. Statistical significance is presented in the
figures in the following way: *p < 0.05, **p < 0.01 and
***p < 0.001.
Results
Establishment of the invasion assay and comparison of the 
invasive properties of different tumorigenic cell types
Tumor cells were seeded on top of a pre-formed rat tail
collagen gel and allowed to adhere. In previously
described 3D invasion assays the tumor cells are then
allowed to invade the underlying layer of collagen [10].
Establishment of the invasion assay and comparison of the invasive potential of different tumor cell types Figure 1
Establishment of the invasion assay and comparison of the invasive potential of different tumor cell types: A. In 
order to assay differences in the invasive potential of different types of tumor cells, the tumor cells are seeded at day 0 on top 
of a gel composed of collagen. Following cell adhesion and spread a second layer of collagen is seeded on top of the cell mon-
olayer. The gels are subsequently cultured between 3 and 9 days and invasion of cells from the monolayer into the collagen 
assayed as described in methods. B. The invasive properties of MDA-MB-435 melanoma cells, MDA-MB-231 and LM2-4 breast 
cancer cells and HT1080 fibrosarcoma cells were compared. Following the seeding of the cells, the invasion of cells from the 
monolayer into the upper and lower collagen gel was measured in intervals of 3 days. Representative low power (10×) pictures 
of perpendicular gel sections in which the tumor cells are stained with eosin-Y are shown.
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However, in order to mimic the in-vivo conditions in
which the tumor cells are completely embedded in tissue,
we poured a second layer of collagen on top of the mon-
olayer of the tumor cells. In essence, the resulting monol-
ayer of tumor cells can be viewed as a two dimensional
tumor that is bordered on each side by a different tissue.
When the completed two layer gels were sectioned per-
pendicularly to the tumor cell monolayer shortly after the
seeding of the cells, the monolayer was seen as a thin line
of cells that clearly defines an origin of migration or start
position (Figures 1A and 1B, Day 0).
To compare the invasive properties of different types of
tumor cells we used MDA-MB-435 cells, which are well
differentiated human melanoma cells that still express
many differentiated markers of melanocytes [14], MDA-
MB-231 breast cancer derived cells and MDA-MB-231
derived LM2-4 cells which differ from the parental cell
line by their increased lung metastases forming ability
[15]. Lastly, we used highly invasive fibrosarcoma derived
HT1080 cells that are generally considered to be among
the most invasive tumor cell types [16,17].
Of these cell lines, the HT1080 cells exhibited, as
expected, the highest invasion rate in our assay while the
MDA-MB-435 cells appeared to be the least invasive (Fig-
ures 1B and 2A). As predicted, parental MDA-MB-231
cells were less invasive than their highly metastatic LM2-4
offspring (Figures. 1B and 2A). The HT1080 and the LM2-
4 cells were clearly much more invasive than the MDA-
Quantitative analysis of the tumor cells invasion assay shown in Figure 1 Figure 2
Quantitative analysis of the tumor cells invasion assay shown in Figure 1. A. The area above and below the cell mon-
olayer was divided into three subsequent 120 μm wide zones as shown in Figure 1A. The number of invading cells in each of 
the zones was determined at three day intervals as described in methods. Each point represents the average number of cells 
counted in at least eight different microscopic fields derived from three separate experiments. B. The average number of each 
of the tumor cell types was determined as a function of time following monolayer formation in microscopic fields using the 
image-pro software as described in methods. C. The number of cells that have invaded each of the zones as a function of time 
is presented here as a percentage out of the total number of cells. Error bars represent the standard error of the mean.
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MB-435 and MDA-MB-231 cells, as evidenced by the
number of cells that successfully migrated more than 120
μm into the surrounding collagen layers after 6 days (Fig-
ures. 1B and 2A). Unlike Boyden chamber assays, which
are usually short term assays, here cells are allowed to
invade and migrate over a period of several days. This is
long enough to allow significant cell proliferation, and
should be controlled for since the invading cells also pro-
liferate. Indeed, the rate of proliferation correlated with
the invasive potential of the cells. HT1080 cells prolifer-
ated at the fastest rate while the proliferation of MDA-MB-
435 cells was the slowest (Figure 2B). To compensate for
the proliferation, we assumed that the rate of proliferation
of the whole cell population, both of cells that did invade
and those that stayed at the origin was similar. We then
divided the number of the invaded cells in each of the
zones by the total number of cells to obtain the percentage
of the entire cell population in each of the zones. By this
criteria too HT1080 and LM2-4 cells are the most invasive
as demonstrated by their ability to traverse longer dis-
tances in the gels at a faster rate (Figure 2C). Interestingly,
In the case of the HT1080 cells, the percentage of cells
which have invaded distant zones was the same after 3
days or after 9 days (Figure 2C), suggesting that there may
exist a subpopulation of cells that migrates very rapidly
while another subpopulation does not migrate as
robustly, and that all the cells found at distant locations
are derived from this rapidly migrating subpopulation.
Inhibition of Loxl2 expression in several invasive tumor cell 
types inhibits invasiveness
Loxl2 is a member of the lysyl-oxidase family of enzymes.
We have previously characterized it as a promoter of
tumor cell invasiveness [13]. The increased invasiveness
was subsequently attributed to Loxl2 induced inhibition
of E-cadherin expression in tumor cells [18,19]. Inhibi-
tion of Loxl2 expression in highly invasive HT1080 and
LM2-4 cells as well as in MDA-MB-231 cells using a spe-
cific shRNA species directed against Loxl2 (Figure 3A)
induces morphological changes resembling mesenchymal
to epithelial transition (Figure 3B). These changes were
accompanied by very strong inhibition of the invasive
ability of these three cell types (Figure 4A and 4B) indicat-
ing that the assay faithfully correlates with in-vivo obser-
vations and confirming that up-regulation of Loxl2 in
tumor cells is in all likelihood a major cause of enhanced
tumor cell invasiveness. To verify these results by a differ-
ent assay we measured the effects of the inhibition of
Loxl2 expression on the invasiveness of HT1080 cells
using a Boyden chamber invasion assay. In the Boyden
chamber assay too we found that inhibition of Loxl2
expression strongly inhibits the invasiveness of the
HT1080 cells (Figure 4C).
The composition of the extracellular matrix has a major 
effect on tumor cell invasiveness
Invasive tumor cells migrate through tissues that differ in
the composition of their ECM. Fibronectin and laminin
are extracellular adhesion molecules that associate with
collagen [20]. We have utilized the asymmetric character
of our invasion assay in order to compare the effects of
fibronectin and laminin on tumor cell invasiveness. We
added laminin or fibronectin selectively to the upper or
lower collagen layers or to both layers and examined the
relative effects of the adhesion molecules on the invasive
behavior of LM2-4 breast cancer cells. The LM2-4 cells
migrated vigorously into collagen that contained
fibronectin but invaded much less successfully into colla-
gen layers containing laminin. Thus, when the upper col-
lagen layer contains fibronectin and the lower laminin,
the cells migrated more aggressively into the upper gel
layer and vice versa (Figures 5A and 5B). Interestingly,
laminin also acts as an inducer of tumor cell invasion
although it is less potent than fibronectin, since the LM2-
4 cells invade laminin containing collagen more effi-
ciently than collagen that does not contain any added
adhesion molecules (Figures 5C and 5D).
Tissues also contain many different types of normal cells
which can in turn affect the behavior of invading tumor
cells. Once again we took advantage of the asymmetric
nature of the assay to set up an experiment designed to
determine if fibroblasts secrete attractive factors that
enhance tumor cell invasiveness. We labeled MDA-MB-
231 breast cancer cells which normally do not display a
highly invasive behavior (Figure 1B) with a fluorescent
dye and we then embedded a monolayer of these cells in
collagen. Above the empty upper layer of collagen we
formed another layer of collagen that contained a suspen-
sion of normal human foreskin fibroblasts labeled with a
different fluorescent dye as depicted (Figure 6A). The cells
were allowed to migrate for four days and perpendicular
sections of the gels were then observed by fluorescent
microscopy. It can be seen that the tumor cells migrated
preferentially towards the fibroblasts suggesting that
fibroblasts secrete attractive factors that are sensed by the
breast cancer cells and induce directional invasion
towards the fibroblasts. In contrast, in the absence of
fibroblasts there was much less invasion (Figure 6B and
6C). In this experiment too the asymmetric nature of the
assay is utilized to demonstrate that the breast cancer cells
migrate much less vigorously into the lower collagen layer
which does not contain fibroblasts (Figure 6B).
Discussion
The transition from the non-invasive to the invasive phe-
notype marks a fundamental change in tumor progression
since tumor cell invasiveness is a pre-requisite for success-
ful metastasis to distant organs [1]. Therefore, the under-BMC Cancer 2009, 9:415 http://www.biomedcentral.com/1471-2407/9/415
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standing of the molecular mechanisms that govern the
shift from the non-invasive to the invasive phenotype,
and the identification of potential drugs able to inhibit
tumor cell invasiveness are of great interest.
While animal experiments provide much data concerning
tumor progression, they are inherently expensive and
slow. In addition, in-vivo it is difficult to study molecular
mechanisms due to the complexity of the environment
and due to the variability of individual animals. Thus, the
development of cheap quantitative in-vitro models that
mimic as closely as possible the in-vivo situation yet
afford precise control of experimental conditions is of
prime importance for the study of the molecular mecha-
nisms that regulate tumor progression. Like many other
invasion assays, the 3D assay system we have devised
relies upon the study of the behavior of tumor cells in gels
containing ECM components in the presence or absence
of stromal cells. The main advantage over previous assays
results from the initial layout in which the tumor cells are
placed as a monolayer between upper and lower gels. This
confers an asymmetric nature to the assay since the com-
position of the upper and lower gels can be varied inde-
pendently. This means that experiments designed to
compare the effects of micro environmental factors can be
examined in a single assay system.
An additional advantages is the existence of a sharply
defined origin from which invasion begins. This means
that the results of experiments are easily quantifiable.
Additionally, the whole cell population is monitored
which is of particular importance for the characterization
Inhibition of Loxl2 expression in tumor cells induces transition from a mesenchymal to epithelial like morphology Figure 3
Inhibition of Loxl2 expression in tumor cells induces transition from a mesenchymal to epithelial like morphol-
ogy. A. The expression of Loxl2 in MDA-MB-231 and LM2-4 breast cancer cells and HT1080 fibrosarcoma cells was inhibited 
following infection with lentiviruses producing the Loxl2 targeting shRNA TRCN46195 (sh-195). Control cells were infected 
with a lentiviral vector carrying the control unrelated shRNA SHC002 (sh-c). Shown are western blots of cell lysates derived 
from control versus sh-195 infected cells probed with a polyclonal antibody directed against Loxl2 [13]. B. Phase contrast 
microscopy pictures of cultures of HT1080, LM2-4 and MDA-MB-231 cells stably expressing the control shRNA SHC002 or 
the Loxl2 silencing shRNA TRCN46195.
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of subpopulations of tumor cells and constitutes a major
advantage over Boyden chamber styled assays. However,
there are also disadvantages. The assay is relatively slow
compared to Boyden chamber based assays which can
generate results within hours, and is technically more
complicated as it requires sectioning in a cryostat. This last
disadvantage may be overcome in the future by the appli-
cation of existing optical sectioning tools and appropriate
software [21].
To demonstrate the usefulness of this assay we deter-
mined how inhibition of Loxl2 expression affects the
invasiveness of cancer cells. Loxl2 is a known promoter of
tumor cell invasiveness [13]. Loxl2 over-expression affects
the degradation of the transcription factor snail resulting
in the inhibition of the expression of E-cadherin, a known
marker of epithelial to mesenchymal transition and a key
regulator of tumor cells invasiveness [18,19,22]. How-
ever, this is probably not the only mechanism by which
Loxl2 modulates tumor cell invasiveness and more studies
are required in order to understand the mechanisms by
which Loxl2 enhances tumor cells invasiveness. We have
inhibited the expression of Loxl2 in several types of breast
cancer cells and in cells derived from fibrosarcoma using
a shRNA species specific for Loxl2 which strongly inhibits
Loxl2 expression. Inhibition of Loxl2 expression strongly
compromised the invasive properties of these cells sug-
gesting that inhibitors of Loxl2 expression may possess
therapeutic value. We also took advantage of the asym-
metric properties of the assay by differentially adding lam-
Comparison of the 3D invasion assay and the Boyden chamber invasion assay Figure 4
Comparison of the 3D invasion assay and the Boyden chamber invasion assay. A. MDA-MB-231, LM2-4 and 
HT1080 cells infected with lentiviruses encoding the control shRNA SHC002 (sh-control) or lentiviruses encoding the Loxl2 
specific shRNA TRCN46195 (sh-Loxl2) were seeded as monolayers in collagen as described under Figure 1. After 4 days the 
gels frozen and were sectioned perpendicular to the cell monolayer. Shown are cryostat sections in which the cells were 
stained with eosin-Y. Three independent experiments were performed with similar results. B. The number of tumor cells 
infected with a control shRNA or with the Loxl2 specific shRNA encoding lentiviruses was determined as described in meth-
ods. Each histogram represents the average number of invading cells determined from examination of eight to twelve micro-
scopic fields derived from three different experiments. C. Representative pictures of HT1080 fibrosarcoma cells infected with 
lentiviruses encoding control (sh-control) or Loxl2 targeting (sh-Loxl2) shRNA species that have invaded and crossed the filter 
of Boyden chambers is shown. The histogram shows the average number of cells that transversed the Boyden chamber filter in 
two independent experiments. Error bars represent the standard error of the mean. *** p < 0.001.
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inin or fibronectin to the upper or lower collagen layers in
order to compare directly the effects of fibronectin and
laminin on the invasive ability of breast cancer cells. Inter-
estingly, we found that the assay provided clear evidence
suggesting that both fibronectin and laminin potentiate
the invasion of breast cancer cells into type I collagen con-
taining gels, and that fibronectin is a significantly more
potent inducer of the invasiveness of these cells as com-
pared to laminin. This result suggests that breast cancer
cells probably do not adhere well to type I collagen and
that this limits their invasive potential. This observation
opens the way for more extensive comparative studies
designed to determine the effects of different ECM com-
ponents on tumor cell invasiveness. Our results correlate
well with studies showing that decreased production of
laminin and expression of fibronectin are correlated with
poor prognosis in breast cancer tumors [8,23,24],
although there are also studies that report different obser-
vations [25].
We exploited the asymmetric nature of our assay to deter-
mine if normal fibroblasts such as those encountered in
normal tissues surrounding tumors, as opposed to tumor
associated fibroblasts, can attract invading breast cancer
cells and thus promote tumor cell invasiveness. Tumor
associated fibroblasts have been reported to enhance
tumor invasiveness by various mechanisms [26-29].
Implantation of normal foreskin derived fibroblasts on
Comparison of the effects of fibronectin and laminin on tumor cells invasiveness Figure 5
Comparison of the effects of fibronectin and laminin on tumor cells invasiveness. A. LM-2-4 cells (6 × 104cells/well) 
were seeded between two collagen layers as described in methods. Laminin (0.1 mg/ml) or fibronectin (0.1 mg/ml) were selec-
tively added to the upper or lower collagen layers or to both collagen layers. The experiment was terminated after 3 days and 
invading cells stained in gels as described. B. LM2-4 cells that invaded the upper or lower collagen gels were counted as 
described in methods. Shown are the results of two independent experiments. At least twelve microscopic fields were counted 
to obtain individual average data points. C. The effects of laminin and fibronectin on the ability to invade collagen gels were 
measured as described under A. D. Quantification of the relative effects of laminin and fibronectin on the invasiveness of LM2-
4 cells was performed as described under B. Error bars represent the standard error of the mean. *p < 0.05, *** p < 0.001.
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top of a monolayer of MDA-MB-231 cells attracted tumor
cells that began to invade the collagen matrix towards
fibroblasts located above the tumor cell monolayer but
not downwards into an empty collagen layer located
below the monolayer. Here again the advantage of the
asymmetric nature of the assay is clearly demonstrated
since the effects can be easily seen and compared with an
internal control afforded by the empty lower layer of col-
lagen.
In conclusion, we have established a novel quantitative
in-vitro 3D assay designed to study modulators of tumor
cell invasiveness.
Conclusion
The in-vitro invasion assay we describe here enables relia-
ble and quantitative assessment of the invasive potential
of cancer cells. Contrary to the widely used Boyden cham-
bers assay it enables assessment of the invasive potential
of the whole tumor cell population. The asymmetric
nature of the assay allows easy detection of attractive or
repulsive effects induced by various cell types, ECM com-
ponents, or purified proteins in a microenvironment that
can be fashioned to closely resemble the microenviron-
ment encountered by migrating tumor cells in-vivo. We
have used it to compare the effects of laminin and
fibronectin as well as fibroblasts on the invasiveness of
breast cancer cells and have shown that fibronectin is a
better enhancer of breast cancer cells invasion as com-
Fibroblast derived soluble factors attract MDA-MB-231 breast cancer cells and enhance their invasiveness Figure 6
Fibroblast derived soluble factors attract MDA-MB-231 breast cancer cells and enhance their invasiveness. A. 
Schematic representation of the 3D invasion assay shown in panel B. B. MDA-MB-231 cells were labeled with DiI (green fluo-
rescence) and normal fibroblasts labeled with DiAsp (red fluorescence). Tumor cells were seeded in collagen gels in the pres-
ence or absence of fibroblasts as described in methods. Shown is a perpendicular section of a representative collagen gel 
examined with a fluorescent microscope. C. Quantification of tumor cells induced to invade by fibroblasts was performed as 
described under Figure 2.
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pared to laminin, and that secreted factors derived from
fibroblasts attract invading breast cancer cells.
Abbreviations
3D: Three dimensional; ECM: Extracellular matrix; EMT:
epithelial to mesenchymal transition; Loxl2: Lysyl-oxidase
like protein-2.
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